Royce & Associates LP Has $9.42 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Royce & Associates LP lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 58.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 196,999 shares of the biopharmaceutical company’s stock after purchasing an additional 72,988 shares during the period. Royce & Associates LP owned 0.15% of Halozyme Therapeutics worth $9,419,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of HALO. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $29,000. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at $29,000. Smartleaf Asset Management LLC raised its position in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter worth about $69,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 322 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Down 0.7 %

HALO stock opened at $62.54 on Wednesday. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $65.53. The business has a 50-day simple moving average of $57.53 and a 200 day simple moving average of $54.61. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The company has a market cap of $7.70 billion, a PE ratio of 18.23, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This represents a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the sale, the director now owns 33,611 shares in the company, valued at $1,972,629.59. This represents a 12.95 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock worth $1,754,451 over the last three months. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Finally, Benchmark reissued a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.